Insurance Coverage and Processing Packaging Presentation 
European Pharmaceutical Review
MARCH 28, 2024
Measuring treatment effect in rare disease populations presents many methodological challenges due to small sample sizes and heterogeneity of the study population. How does the qualification package support more meaningful endpoints and rare disease research as a result?
Express Pharma
JANUARY 12, 2024
Expectation #2: Bring GST rate on APIs at par with the formulations – At present, APIs attract a higher GST rate of 18 per cent vis-à-vis formulations that attract a lower rate (12 per cent/5 per cent), leading to accumulation of credit for the pharma industry.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Putting Patients First Blog
MARCH 18, 2024
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
Putting Patients First Blog
MARCH 18, 2024
The NHC supports the development and use of processes and tools that enhance beneficiary experience, making interactions with the MPPP smoother and more intuitive for all beneficiaries. Similarly, updating the Explanation of Benefits to include visual aids and examples will clarify MPPP’s impact on cost-sharing and coverage.
Pharmaceutical Technology
FEBRUARY 7, 2023
Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.
Expert insights. Personalized for you.
52 
Let's personalize your content